Lipigon Pharmaceuticals has entered into a Target Validation Research Agreement with the German antisense therapeutics company Secarna Pharmaceuticals.
The goal is to co-develop a drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases.
“We are very pleased for this exciting opportunity to work together with Secarna, bringing forward what we believe will be the most powerful plasma lipid lowering agent on the market”, stated CEO and co-founder Stefan K. Nilsson. He added, “This agreement utilizes Secarna’s state of the art next generation antisense platform technology and our lipid biology expertise. The lead time from choosing targets to actually validating the product candidate is exceptionally short, therefore the antisense approach is extremely attractive to us”.
“Targeting lipid disorders via antisense oligonucleotides is an extremely attractive proposition,” commented Secarna’s CEO Jonas Renz. “We are delighted to leverage Lipigon’s unique insights into lipid biology and apply our proprietary platform to generating highly potent and safe lead molecules”.
Photo of Stefan Nilsson, CEO Lipigon
Source: Biotech Umeå